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Propranolol, infantile haemangiomas,
and serendipity: new use for an old
drug
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Capillary haemangiomas are benign lesions that may occur anywhere on the skin, may grow rapidly in the
first two years of life and may impair vital organs. Propranolol has been recently discovered to shrink these
lesions effectively. We report the first such patient treated in Malta with this drug.
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C
apillary haemangiomas (strawberry nevus) are
benign, haemartomatous endothelial cell neo-
plasms and occur as raised, red, lumpy lesions
that may occur anywhere on the skin with a predilection
(50%) for the head and neck area. They constitute the
most common orbital/periorbital tumours of childhood.
Haemangiomas are found in approximately 12% of all
neonates, manifesting between 1 and 4 weeks of age (1).
Some may grow rapidly in the first 2 years in both size,
depth, and elevation above the skin surface (proliferative
phase), but then start to regress with 60% disappearing by
5 years of age and over 90% by 9 years age (involutional
phase) (2). These lesions are common in Caucasians and
in females rather than in males (5:1) (1). Because of their
high rate of spontaneous resolution, treatment is only
limited to those that impair sensory (obstruction of an
eye may lead to irreversible amblyopia), vital organs, or
that produce significant complication(s). Treatment in
such cases was traditionally with the use of corticoster-
oids, alpha-interferon, and vincristine, all with limited
success. Plastic surgery is equally disappointing (3, 4).
In 2009, a group of researchers who treated an infant
with a large nasal haemangioma with corticosteroids
iatrogenically induced hypertrophic obstructive cardio-
myopathy. On commencing standard treatment with
propranolol, they observed rapid involution of the
haemangioma and this prompted the treatment of a
small series of children (up to 5 mg/kg/d), with equal
success (5). We report on one of the first patients treated
locally with this old drug in order to raise awareness of
this ‘novel’ treatment.
Patient
Our patient was a 6-month-old female Libyan infant who
was delivered uneventfully in Malta at St. James Hospital
in Sliema. Shortly after the baby returned to Libya, the
parents noted a capillary haemangioma on the lateral
aspect of the left arm. This lesion rapidly proliferated and
ulcerated with a serous, non-infected discharge, probably
as a result of frequent trauma as would be expected in an
infant of this age with a lesion at this location. The lesion
was tense, reddish purple all over, measured 5344 mm,
and was elevated by 20 mm above the skin surface (Fig. 1).
Due to the ulceration, discharge, and possibility
of infection, propranolol was commenced at a dose of
1 mg/kg/dose thrice daily. Blood pressure remained stable
and propranolol was increased to 2 mg/kg/dose thrice
daily in the second week of treatment. The lesion
exhibited rapid involution with shrinkage and reappear-
ance of patches of normal skin. The child developed
varicella and this did not have any effect on the lesion
or treatment whatsoever. Propranolol was stopped after
6 weeks (Fig. 2) with the lesion measuring 4020 mm
and elevated 10 mm above the skin.
Discussion
The practice of any aspect of science  including that of
medicine  requires the independent replication of new
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ideas and results and, if these are confirmed, a paradigm
shift occurs with the rejection of conventional theory and
acceptance of the new standard. Breakthroughs com-
monly occur serendipitously in all branches of science
including medicine. Serendipity is the propensity for
making fortuitous discoveries while looking for some-
thing unrelated. An important aspect is the ‘sagacity’ of
being able to link together apparently unrelated facts to
come to a valuable conclusion. The list of such discoveries
is endless including, for example, the accidental discovery
of penicillin, the useful side effect of minoxidil for the
promotion of hair growth in a drug initially developed for
the treatment of hypertension, and the useful side effect
of penile erection with sildenafil, a drug initially devel-
oped to treat coronary artery disease (6).
The mechanisms of haemangioma proliferation are
uncertain, and it is believed that such growth is regulated
through mediators such as basic fibroblast growth factor
(bFGF) and vascular endothelial growth factor (VEGF)
(7). Propranolol is a non-selective beta-blocker developed
in the late 1950s and possible actions for promoting
haemangioma involution, while uncertain, may include
an immediate vasoconstriction within the lesion resulting
in rapid colour change and palpable softening, decreased
expression of VEGF and bFGF genes, and triggering of
apoptosis of the endothelial cells contained within the
lesion (7).
Propranolol is an effective and well-tolerated treatment
in the management of selected cases of severe haeman-
giomas in infancy. Side effects include bradycardia,
hypotension, and hypoglycaemia in very young infants
and neonates, but these effects are typically mild and
short lived. Indeed, after more than 40 years of clinical
use in infants, there is no documented case of death or
serious cardiovascular disease as a direct result of
exposure to a beta-blocker in the literature (8). In our
patient, treatment was stopped after 6 weeks as the lesion
had involuted significantly with no residual ulceration,
and the natural history of such lesions is spontaneous
resolution. We hope that this publication will raise
awareness among clinicians in Libya and in Malta with
regard to this new treatment for significant haemangio-
mas by this old and inexpensive drug.
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Fig. 1. Initial appearance of haemangioma prior to
commencing oral propranolol.
Fig. 2. Appearance of haemangioma after 6 weeks of
treatment with oral propranolol.
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